Optimizing the use of carbapenems in the face of increasing Gram-negative resistance
Citation:
Critical Care
2008
12(Suppl 4):S1
Volume 12 Supplement 4
Optimizing the use of carbapenems in the face of increasing Gram-negative resistance
Reviews
Edited by Stephan Harbarth
Publication of this supplement has been sponsored by Ortho-McNeil, Inc.
-
-
Pharmacodynamic optimization of β-lactams in the patient care setting
In order to eradicate an infecting organism, it is necessary to achieve or maintain concentrations of an antibiotic in vivo that exceed the minimum inhibitory concentration (MIC) for the organism. Duration of exp...
Citation: Critical Care 2008 12(Suppl 4):S2 -
An overview of harms associated with β-lactam antimicrobials: where do the carbapenems fit in?
The US Institute of Medicine's focus on patient safety has motivated hospital administrators to facilitate a culture of safety. As a result, subcommittees of the pharmacy and therapeutics committee have emerge...
Citation: Critical Care 2008 12(Suppl 4):S3 -
Gram-negative antibiotic resistance: there is a price to pay
Resistance rates are increasing among several problematic Gram-negative pathogens that are often responsible for serious nosocomial infections, including Acinetobacter spp., Pseudomonas aeruginosa, and (because o...
Citation: Critical Care 2008 12(Suppl 4):S4 -
The role of carbapenems in initial therapy for serious Gram-negative infections
The treatment of patients with serious Gram-negative infections must be both prompt and correct. Numerous studies have demonstrated that mortality risk is significantly increased when the initial antibiotic re...
Citation: Critical Care 2008 12(Suppl 4):S5
Follow
- ISSN: 1364-8535 (electronic)